Prediction model of hepatocellular carcinoma development in chronic hepatitis B virus infection in a Spanish cohort.

Autor: Gavilán P; Universidad de Málaga, IBIMA-Plataforma BIONAND, Departamento de Farmacología y Pediatría, Facultad de Medicina, Campus de Teatinos s/n, 29071 Málaga, Spain., Gavilán JC; Departamento de Medicina Interna, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Hospital Internacional Vithas Xanit, Benalmádena, Spain. Electronic address: jc_gavilan@hotmail.com., Arnedo R; Departamento de Medicina Interna, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Hospital Internacional Vithas Xanit, Benalmádena, Spain., Clavijo E; Universidad de Málaga, IBIMA-Plataforma BIONAND, Departamento de Microbiología, Facultad de Medicina, Campus de Teatinos s/n, 29071 Málaga, Spain., Viciana I; Departamento de Microbiología, Hospital Universitario Virgen de la Victoria, Málaga, Spain., González-Correa JA; Universidad de Málaga, IBIMA-Plataforma BIONAND, Departamento de Farmacología y Pediatría, Facultad de Medicina, Campus de Teatinos s/n, 29071 Málaga, Spain.
Jazyk: English; Spanish; Castilian
Zdroj: Medicina clinica [Med Clin (Barc)] 2024 Dec 27; Vol. 163 (12), pp. 609-616. Date of Electronic Publication: 2024 Oct 18.
DOI: 10.1016/j.medcli.2024.07.022
Abstrakt: Introduction and Objectives: To identify risk factors associated with the development of hepatocellular carcinoma (HCC) in an unselected cohort of patients with chronic B virus infection (CHB) in Spain. A predictive model was developed to assess the risk of HCC.
Material and Methods: A prospective open-cohort study recruited 446 unselected patients with chronic hepatitis B infection from two hospitals in Málaga (Spain). The follow-up time ranged from 0.5 to 31.5 years (mean: 13.8; SD: 9.5; median: 11.4 years). We used a Cox proportional hazard model to estimate the multivariable-adjusted hazard ratios of risk factors associated with the development of liver cancer and developed a clinical score, (HCCB score) to determine the risk of liver cancer, that categories patients into two risk levels for the development of HCC. We compared the diagnostic accuracy of our model with other previously published.
Results: During the follow-up period, 4.80% of the patients developed liver cancer (21 out of 437), 0.33 cases per 100 patient-years. Multivariate Cox regression analysis revealed that age >45 years, male gender, hepatitis C coinfection, alkaline phosphatase >147IU/L, Child score >5 points, glucose >126mg/dL, and a viral load >4.3 log 10 IU/mL were independent risk factors. A risk score has been developed with a high predictive capacity for identifying patients at high risk of developing hepatocellular carcinoma. AUROC 0.87 (95% CI: 0.79-0.95).
Conclusions: An HCCB score greater than 5.42 points identifies a subgroup of chronic hepatitis B patients at high risk of developing liver cancer, who could benefit from screening measures for the early diagnosis of HCC.
(Copyright © 2024 Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: